This bill makes targeted, technical amendments to the FDA Food Safety Modernization Act’s user‑fee provisions so the Food and Drug Administration can actually assess and collect fees tied to reinspections and recalls. It fixes fee formulas, establishes a small‑business discount, dedicates fee streams to particular activities (oversight versus the Voluntary Qualified Importer Program), raises statutory caps, and clarifies which inspections qualify as ‘‘reinspections.’n
For companies and compliance officers, the changes matter because they convert previously ambiguous statutory language into concrete billing mechanics: fixed fee floors for certain categories, a one‑third fee for qualifying small businesses, a requirement that FDA publish adjusted fee schedules, and a deadline for guidance on how firms claim reductions. The net effect is more predictable (and enforceable) fee authority for FDA — and clearer cost exposure for facilities and importers that trigger reinspections or recalls.
At a Glance
What It Does
The bill amends 21 U.S.C. 379j–31 to set $15,000 baseline fees for several user‑fee categories (adjusted annually), requires subsection (a)(1)(C) fees to equal 100% of program costs, creates a one‑third fee for qualifying small businesses, and directs how fee revenue may be used. It also raises two statutory fee caps and defines ‘‘reinspection’’ and ‘‘importer.’n
Who It Affects
Domestic and foreign food facilities subject to FDA inspection, importers covered by the Foreign Supplier Verification Program (FSVP), and companies that trigger a reinspection or recall. FDA will also be affected operationally by new publication and guidance obligations.
Why It Matters
Professionals need to know exact fee exposure, what qualifies for the small‑business discount, and which activities fees will fund. The bill converts policy ambiguity into clear billing rules that change compliance budgets and the way firms document and contest inspection classifications.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill rewrites the FSMA user‑fee methodology to make fee amounts and uses explicit. For three of the fee categories it sets a $15,000 per‑instance baseline for fiscal year 2026 and thereafter, subject to an annual adjustment factor; for the remaining category—fees related to the voluntary qualified importer program (VQIP)—the statute requires fees to be set equal to FDA’s estimate of 100 percent of the program’s costs for that fiscal year.
That structure forces two different approaches: fixed baselines for many reinspection/recall events and cost‑recovery for VQIP administration.
To limit the burden on small operators, the bill creates a uniform small‑business discount: a qualifying facility or importer pays one‑third of the calculated fee. The statute sets objective size thresholds—under 500 full‑time equivalent employees for facilities, and multi‑year average revenue limits for importers (less than $1,000,000 for human‑food importers and less than $2,500,000 for animal‑food importers, both adjusted for inflation).
FDA must publish the adjusted fee schedule annually and, within 270 days of enactment, issue guidance explaining how entities request the reduction; the guidance must be available for immediate implementation to avoid delays in applying the discount.The bill also tightens what counts as a ‘‘reinspection.’’ For domestic and foreign facilities, a reinspection must follow an inspection that received an ‘‘official action indicated’’ (OAI) classification under section 704 and be limited to determining whether the previously identified noncompliance has been corrected. For importers, the analogous trigger is an OAI classification under the FSVP framework.
The statute adds a plain‑language definition of ‘‘importer’’ for fee purposes and clarifies allowable uses of fee revenue: fees from the reinspection/recall categories may be used only for oversight of facilities and importers, while VQIP fees may be used only for VQIP costs. Finally, the bill raises two numerical caps on fee limits (from $20M to $25M and $25M to $30M) and requires FDA to account for carryover fee collections when setting annual fee amounts.
The Five Things You Need to Know
The bill fixes the baseline fee for several reinspection/recall categories at $15,000 for FY2026 and thereafter, adjusted by the statute’s annual adjustment factor.
Section (a)(1)(C) fees (VQIP‑related) must be set to equal 100% of FDA’s estimated VQIP costs for the fiscal year rather than a fixed per‑case amount.
A qualifying small business pays one‑third of the applicable fee; FDA must publish the adjusted fee schedule annually and issue guidance within 270 days to implement fee reductions.
The statutory caps on certain collections increase: the first cap rises to $25 million and the second to $30 million, changing the ceiling on how much FDA may collect overall.
The bill narrows the reinspection trigger: a reinspection is only after an inspection classified as ‘‘official action indicated’’ (OAI) under section 704 for facilities or under FSVP section 805 for importers, and is limited to verifying remediation.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short title: the FSMA Fee Technical Corrections Act. This is a housekeeping provision that identifies the bill for citation and reference.
Fee methodology and amounts
Rewrites paragraph (2) of 21 U.S.C. 379j–31(b) to set baseline fee mechanics. It fixes $15,000 baselines for fees under subsections (a)(1)(A), (B), and (D) (with an annual adjustment factor), and requires subsection (a)(1)(C) fees to equal FDA’s 100% cost estimate for VQIP. Practically, entities can expect recurring per‑event bills for certain reinspections/recalls while VQIP participants face cost‑recovery pricing tied to program budgets. The statute makes fee levels predictable by anchoring them to a dollar figure and an adjustment formula rather than leaving amounts open to agency discretion.
Small‑business discount, schedule, and guidance
Creates a one‑third fee for ‘‘small businesses’’ and requires FDA to publish the annually adjusted reduced fee schedule alongside the user‑fee notice. The bill compels FDA to issue guidance within 270 days explaining how facilities and importers request the reduction and allows the guidance to be implemented immediately. This mechanics package both limits fees for smaller actors and creates a predictable administrative pathway for claiming the discount, but it also requires firms to demonstrate eligibility under the statute’s definition.
Restricted use of fee revenue
Amends paragraph (3) of 21 U.S.C. 379j–31(b) to allocate fee streams: fees from subsections (A), (B), and (D) are restricted to oversight of domestic and foreign facilities and importers; fees from subsection (C) must be used only for VQIP costs. That separation prevents cross‑subsidization between core oversight activities and the voluntary importer program, effectively ring‑fencing funding for VQIP.
Caps and definitions (reinspection, importer, small business)
Raises the two numeric collection caps in 743(c)(4)(A) from $20M to $25M and $25M to $30M, respectively, and substantially clarifies definitions. The bill defines ‘‘reinspection’’ to be a follow‑up inspection after an OAI classification (for facilities under section 704 and for importers under FSVP section 805) and limits reinspections to assessing remediation. It adds a statutory importer definition tied to FSVP coverage and sets objective small‑business thresholds: facilities under 500 FTEs, human‑food importers averaging under $1M (three‑year average, inflation adjusted), and animal‑food importers averaging under $2.5M (three‑year average, inflation adjusted). These definitions reduce ambiguity about who is chargeable and who qualifies for reduced fees.
This bill is one of many.
Codify tracks hundreds of bills on Agriculture across all five countries.
Explore Agriculture in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Small domestic and foreign facilities (under 500 FTEs): They receive a one‑third reduction in per‑event fees, lowering direct reinspection/recall cost exposure and helping smaller processors manage cash flow after compliance events.
- Small importers of human and animal food (below the statute’s multi‑year revenue thresholds): They get the one‑third fee reduction and clearer, published procedures for claiming it, which reduces uncertainty about post‑inspection bills.
- VQIP participants and program managers: By requiring VQIP fees to equal program costs and ring‑fencing those fees, the bill provides a stable, dedicated funding stream for the voluntary importer program, supporting program continuity and staffing.
- FDA operational planning: The agency gains clearer statutory authority and mechanics to bill for reinspections and recalls, and a requirement to account for carryover fees reduces the risk of double charging or unlawful overcollection.
Who Bears the Cost
- Large facilities and importers (above the small‑business thresholds): They will pay the full adjusted fee (baseline $15,000 per event, adjusted) and potentially more if they trigger multiple reinspections or recalls.
- Importers and facilities subject to reinspections or recalls: Entities that receive an OAI classification and require follow‑up verification will incur the statutory fee, increasing the financial consequences of enforcement classifications.
- Compliance and legal teams at mid‑sized companies: These teams will need to document eligibility for small‑business status, track multi‑year revenue calculations, and potentially contest inspection classifications—that creates administrative and legal costs.
- FDA (initial administrative load): FDA must publish annual fee schedules, issue guidance within 270 days for fee reductions, and implement systems to credit carryover collections, which will require upfront administrative and IT work without an explicit appropriation in the bill.
Key Issues
The Core Tension
The central dilemma is balancing predictable, enforceable funding for FDA’s oversight against fairness and administrative simplicity for regulated entities: the bill tightens fee authority and creates protections for small firms, but those same clarifications concentrate charges on specific inspection outcomes (OAI), create complex eligibility calculations, and shift more implementation complexity onto FDA and industry.
The bill resolves several textual gaps in the FSMA user‑fee statute but leaves operational and interpretive questions that could affect implementation. First, tying reinspection authority to an ‘‘official action indicated’’ classification narrows when FDA can charge, but also concentrates financial consequence on that classification.
Disagreements over OAI determinations could therefore trigger more appeals and contestation, shifting costs into dispute resolution rather than straightforward compliance. Second, the importer small‑business test relies on a combined calculation of multi‑year sales plus U.S. market value of imported food; that metric will require detailed guidance and data sources to avoid inconsistent eligibility determinations across firms and commodity types.
Third, the split between fixed baseline fees and a 100% cost‑recovery approach for VQIP creates differing incentives: fixed fees deliver predictability but may under‑ or over‑recover relative to actual inspection activity, while cost‑recovery fees for VQIP tie participant costs to FDA budget estimates and could fluctuate year‑to‑year. The carryover credit provision improves fairness by preventing double collection, but it adds volatility to annual fee calculations and complicates industry budgeting.
Finally, raising statutory caps increases headroom but does not eliminate the possibility that fee revenue and oversight needs will diverge, particularly if inspection workload rises faster than fee indexing.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.